News

Dr. Hong and Ceci are thrilled to announce that the Phase 1 Novel Drug Clinical Trial conducted at HKU Phase 1 Centre was approved by the China Food and Drug Administration (CFDA)! It proves that the contribution of healthy volunteers are rewarding!

A Phase 1 clinical trial on novel hepatitis C drug was completed at HKU Phase 1 Clinical Trials Centre in 2015. It provided important data on drug metabolism of Chinese people which expedited the completion time of clinical studies in China. The drug could finally be approved by CFDA in April 2018.

The drug received its first global approval from the U.S. Food and Drug Administration (FDA) in January 2016 and subsequently its registration in Hong Kong from the Department of Healthy in January 2018. It took only merely 2 years for the drug to obtain the approval to register in China after its first global approval. More patients could benefit from it and the result was truly encouraging to all.

We would like to thank all healthy volunteers who participated in this clinical study for your precious time and contribution in supporting the drug discovery!

U.S. Food and Drug Administration: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm
Department of Health, Hong Kong: http://www.drugoffice.gov.hk/eps/drug/productDetail/en/consumer/98948

Please like and share our Facebook link to your family members, friends and colleagues who are interested in healthcare information and medical research. Stay tuned to our posts and we are here to answer your inquiries on Facebook!

https://www.facebook.com/hkuctc/